{"title":"Grenz Ray Therapy for Darier Disease and Hailey-Hailey Disease: A Case Series of Three Patients","authors":"Conor Larney, Dale Jobson, Michael Webster","doi":"10.1111/ajd.14407","DOIUrl":"10.1111/ajd.14407","url":null,"abstract":"","PeriodicalId":8638,"journal":{"name":"Australasian Journal of Dermatology","volume":"66 1","pages":"e28-e31"},"PeriodicalIF":2.2,"publicationDate":"2024-12-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142891579","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Clinical photography plays a crucial role in dermatology by aiding in diagnosis, monitoring treatment progress and providing valuable visual documentation for research and patient education. This article outlines key photographic techniques, equipment options and best practices tailored for dermatologists to improve clinical outcomes through high-quality imagery.
{"title":"Enhancing Dermatological Practice Through Photography: Essential Techniques and Tools","authors":"Ishana Dixit, Elizabeth Dawes-Higgs","doi":"10.1111/ajd.14408","DOIUrl":"10.1111/ajd.14408","url":null,"abstract":"<div>\u0000 \u0000 <p>Clinical photography plays a crucial role in dermatology by aiding in diagnosis, monitoring treatment progress and providing valuable visual documentation for research and patient education. This article outlines key photographic techniques, equipment options and best practices tailored for dermatologists to improve clinical outcomes through high-quality imagery.</p>\u0000 </div>","PeriodicalId":8638,"journal":{"name":"Australasian Journal of Dermatology","volume":"66 1","pages":"21-24"},"PeriodicalIF":2.2,"publicationDate":"2024-12-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142880915","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Adult-onset Still’s disease (AOSD) is a rare autoinflammatory systemic disorder classically characterised by inflammatory polyarthritis, daily fevers and a transient asymptomatic salmon-pink maculopapular rash that typically arises with the onset of fevers. We report a case of AOSD presenting with a severely pruritic urticarial eruption starting 6 weeks prior to the onset of fever and arthritis and complicated by macrophage activation syndrome. This case highlights the importance of early recognition of diverse cutaneous manifestations of AOSD to facilitate timely diagnosis and treatment to improve disease outcomes.
{"title":"Persistent urticarial eruption preceding systemic features of adult-onset Still's disease: A case report","authors":"Amreeta Kaur BBiomed (Hons), MD, Mathuja Bavanendrakumar BSc, MBBS, FRACP, Shereen Oon MBBS, BMedSci, FRACP, PhD, Emma Veysey MBChB, MRCP, MPH, FACD","doi":"10.1111/ajd.14397","DOIUrl":"10.1111/ajd.14397","url":null,"abstract":"<p>Adult-onset Still’s disease (AOSD) is a rare autoinflammatory systemic disorder classically characterised by inflammatory polyarthritis, daily fevers and a transient asymptomatic salmon-pink maculopapular rash that typically arises with the onset of fevers. We report a case of AOSD presenting with a severely pruritic urticarial eruption starting 6 weeks prior to the onset of fever and arthritis and complicated by macrophage activation syndrome. This case highlights the importance of early recognition of diverse cutaneous manifestations of AOSD to facilitate timely diagnosis and treatment to improve disease outcomes.</p>","PeriodicalId":8638,"journal":{"name":"Australasian Journal of Dermatology","volume":"66 2","pages":"90-92"},"PeriodicalIF":2.2,"publicationDate":"2024-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142876076","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Eyelid allergic contact dermatitis (ACD) attributed to ophthalmic medications is often underreported, which can result in poor outcomes. Patch testing for eyelid ACD requires up-to-date knowledge of potential allergens. The aim of this study was to investigate allergens in ophthalmic medicaments in New Zealand.
Methods
We conducted a cross-sectional review of ophthalmic medicaments available in New Zealand in October 2023. Prescription and over-the-counter products were catalogued with their respective ingredient lists according to product data sheets. Products unapproved for use as per Section 29 of the Medicines Act 1981, or that were unavailable for purchase were excluded. Ingredients were classified according to their function. Allergens in the New Zealand Baseline Series Extended (NZBSE) were recorded.
Results
Seventy-three topical ophthalmic medicaments were identified with a total of 143 formulations (brands). Twenty-eight formulations were excluded, leaving a total of 67 topical medicaments (115 formulations) for analysis. Fifty-eight per cent of formulations contained at least one NZBSE allergen. The most frequently identified NZBSE allergen was benzalkonium chloride (contained in 48% of formulations), followed by propylene glycol (6%), lanolin (4%), parabens (4%), caine anaesthetics (2%), neomycin sulphate (2%), and cetearyl alcohol (1%).
Conclusions
The majority of ophthalmic preparations contain known allergens. Patch test series must be based on local data and revised regularly to ensure the diagnostic accuracy of patch testing. Patch testing patient's own products is imperative.
{"title":"Allergens in ophthalmic medicaments in New Zealand","authors":"Carneshika Bernadette Hettiaratchi BSc, MBChB, Harriet Kennedy BHB, MBChB, FRACP","doi":"10.1111/ajd.14395","DOIUrl":"10.1111/ajd.14395","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background/Objectives</h3>\u0000 \u0000 <p>Eyelid allergic contact dermatitis (ACD) attributed to ophthalmic medications is often underreported, which can result in poor outcomes. Patch testing for eyelid ACD requires up-to-date knowledge of potential allergens. The aim of this study was to investigate allergens in ophthalmic medicaments in New Zealand.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We conducted a cross-sectional review of ophthalmic medicaments available in New Zealand in October 2023. Prescription and over-the-counter products were catalogued with their respective ingredient lists according to product data sheets. Products unapproved for use as per Section 29 of the Medicines Act 1981, or that were unavailable for purchase were excluded. Ingredients were classified according to their function. Allergens in the New Zealand Baseline Series Extended (NZBSE) were recorded.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Seventy-three topical ophthalmic medicaments were identified with a total of 143 formulations (brands). Twenty-eight formulations were excluded, leaving a total of 67 topical medicaments (115 formulations) for analysis. Fifty-eight per cent of formulations contained at least one NZBSE allergen. The most frequently identified NZBSE allergen was benzalkonium chloride (contained in 48% of formulations), followed by propylene glycol (6%), lanolin (4%), parabens (4%), caine anaesthetics (2%), neomycin sulphate (2%), and cetearyl alcohol (1%).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>The majority of ophthalmic preparations contain known allergens. Patch test series must be based on local data and revised regularly to ensure the diagnostic accuracy of patch testing. Patch testing patient's own products is imperative.</p>\u0000 </section>\u0000 </div>","PeriodicalId":8638,"journal":{"name":"Australasian Journal of Dermatology","volume":"66 1","pages":"14-20"},"PeriodicalIF":2.2,"publicationDate":"2024-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142876073","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Alexis Arasu, Andrew Awad, Vanessa Tran, Gayle Ross
Treatment and management outcomes or patients with atopic dermatitis has significantly improved with the inclusion of dupilumab into the pharmaceutical benefits scheme, as a safe and effective treatment. Ocular surface disease remains one of the most frequent adverse events seen with dupilumab, and impacts quality of life and can interrupt treatment. This retrospective review aims to further characterise the experience and risk factors of dupilumab-induced ocular surface disease to inform management and support long-term use for patients, improving overall treatment outcomes.
{"title":"Single-centre retrospective review of dupilumab-induced ocular surface disease in an Australian adult cohort with moderate-to-severe atopic dermatitis","authors":"Alexis Arasu, Andrew Awad, Vanessa Tran, Gayle Ross","doi":"10.1111/ajd.14400","DOIUrl":"10.1111/ajd.14400","url":null,"abstract":"<p>Treatment and management outcomes or patients with atopic dermatitis has significantly improved with the inclusion of dupilumab into the pharmaceutical benefits scheme, as a safe and effective treatment. Ocular surface disease remains one of the most frequent adverse events seen with dupilumab, and impacts quality of life and can interrupt treatment. This retrospective review aims to further characterise the experience and risk factors of dupilumab-induced ocular surface disease to inform management and support long-term use for patients, improving overall treatment outcomes.</p>","PeriodicalId":8638,"journal":{"name":"Australasian Journal of Dermatology","volume":"66 1","pages":"e24-e27"},"PeriodicalIF":2.2,"publicationDate":"2024-12-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142833372","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Erosive vulvovaginal lichen planus is a severe form of Lichen planus (LP) that can result in chronic scarring if not treated. It can cause narrowing of the introitus, resulting in pain, itch, dyspareunia, dysuria, and recurrent urinary tract infections caused by retention of urine. Therefore, an effective and safer therapeutic approach is required. Here, we present a case of refractory erosive vulvovaginal LP, which showed remarkable response to oral tofacitinib, a Janus kinase 1 and 3 (JAK1/3) inhibitor, which was well tolerated.
{"title":"Refractory Vulvovaginal Lichen Planus Responding to Oral Tofacitinib","authors":"Benetta Benny, Anupama Bains, Aasma Nalwa","doi":"10.1111/ajd.14403","DOIUrl":"10.1111/ajd.14403","url":null,"abstract":"<div>\u0000 \u0000 <p>Erosive vulvovaginal lichen planus is a severe form of Lichen planus (LP) that can result in chronic scarring if not treated. It can cause narrowing of the introitus, resulting in pain, itch, dyspareunia, dysuria, and recurrent urinary tract infections caused by retention of urine. Therefore, an effective and safer therapeutic approach is required. Here, we present a case of refractory erosive vulvovaginal LP, which showed remarkable response to oral tofacitinib, a Janus kinase 1 and 3 (JAK1/3) inhibitor, which was well tolerated.</p>\u0000 </div>","PeriodicalId":8638,"journal":{"name":"Australasian Journal of Dermatology","volume":"66 2","pages":"105-106"},"PeriodicalIF":2.2,"publicationDate":"2024-12-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142833343","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Cliff Rosendahl MBBS PhD, Christine Lee Bachelor Nursing, SFC (Skin Cancer Diagnostics), Sarah Coleman Grad Cert Nursing, SFC (Skin Cancer Diagnostics), Aksana Marozava MD, Blake O'Brien MBBS FRCPA
{"title":"The two-step method of digital follow-up of bland skin lesions is a safe and useful tool in melanoma diagnosis","authors":"Cliff Rosendahl MBBS PhD, Christine Lee Bachelor Nursing, SFC (Skin Cancer Diagnostics), Sarah Coleman Grad Cert Nursing, SFC (Skin Cancer Diagnostics), Aksana Marozava MD, Blake O'Brien MBBS FRCPA","doi":"10.1111/ajd.14390","DOIUrl":"10.1111/ajd.14390","url":null,"abstract":"","PeriodicalId":8638,"journal":{"name":"Australasian Journal of Dermatology","volume":"66 1","pages":"48-49"},"PeriodicalIF":2.2,"publicationDate":"2024-12-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142823731","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Usamah M. Afzal MD, Faisal R. Ali MD FRCP PhD, Deemesh Oudit FRCSEd, Roxana Totorean MD, Gareth Evans MD FRCP, John T. Lear FRCP PhD
Metastatic basal cell carcinomas (mBCCs) are exceedingly rare, with an estimated variable prevalence rate between 0.003 and 0.55% among all basal cell carcinomas. Although there are hundreds of reported cases of mBCCs, a dearth of evidence exists of mBCCs in patients with Gorlin syndrome—an autosomal dominant genetic disorder. The purpose of this article was to present the first and largest case series of patients with mBCC in Gorlin. A literature review (LR) compares our data with the existing evidence base to underscore the importance of early surveillance, diagnosis and surgical intervention of suspicious lesions as distant metastases significantly reduce survival rates.
{"title":"Metastatic basal cell carcinomas in Gorlin syndrome—A case series and literature review","authors":"Usamah M. Afzal MD, Faisal R. Ali MD FRCP PhD, Deemesh Oudit FRCSEd, Roxana Totorean MD, Gareth Evans MD FRCP, John T. Lear FRCP PhD","doi":"10.1111/ajd.14401","DOIUrl":"10.1111/ajd.14401","url":null,"abstract":"<p>Metastatic basal cell carcinomas (mBCCs) are exceedingly rare, with an estimated variable prevalence rate between 0.003 and 0.55% among all basal cell carcinomas. Although there are hundreds of reported cases of mBCCs, a dearth of evidence exists of mBCCs in patients with Gorlin syndrome—an autosomal dominant genetic disorder. The purpose of this article was to present the first and largest case series of patients with mBCC in Gorlin. A literature review (LR) compares our data with the existing evidence base to underscore the importance of early surveillance, diagnosis and surgical intervention of suspicious lesions as distant metastases significantly reduce survival rates.</p>","PeriodicalId":8638,"journal":{"name":"Australasian Journal of Dermatology","volume":"66 1","pages":"36-39"},"PeriodicalIF":2.2,"publicationDate":"2024-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142812102","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
<p>The blockade of the interleukin (IL)-17 signalling pathway has revolutionized the treatment of psoriasis with agents such as ixekizumab, and secukinumab (IL-17A inhibitors), brodalumab (IL-17 receptor inhibitor) and bimekizumab (IL-17A and IL-17F inhibitor). Still, primary or secondary failure is observed in some patients forcing us to decide whether we will proceed with an agent that is not an IL-17 inhibitor or perform an intraclass switch.<span><sup>1</sup></span> The available literature on switching between IL-17 inhibitors is generally limited and up to date there are no real-world studies reporting on patients switching to the most recently approved IL-17A/F inhibitor, bimekizumab.<span><sup>2-6</sup></span> Therefore, we aimed to assess whether switching from an IL-17 inhibitor to another (including switching to bimekizumab) is an effective and safe option in a real-world setting.</p><p>We conducted a single-centre, retrospective study of adult patients with moderate-to-severe plaque psoriasis that discontinued an IL-17 inhibitor and were subsequently switched to another agent within the same class. The follow-up period was 104 weeks, with the exception of those that switched to bimekizumab who were followed for up to 52 weeks due to bimekizumab's recent approval in our country.</p><p>In total, 61 patients (40 males, 21 females) were included in the study and their baseline characteristics are presented in Table 1. Twenty-one patients had switched to bimekizumab, 16 to brodalumab, 18 to ixekizumab and 6 to secukinumab. The reason for IL-17 inhibitor discontinuation was primary failure (14 patients), secondary failure (44 patients) and adverse events (AEs) (3 patients). Primary failure was defined as insufficient response (patients not achieving psoriasis area severity index (PASI) 50 at weeks 12–16), according to the medication dosing scheme. Secondary failure was defined as the loss of response of PASI >50% of initial value in a patient who had previously achieved PASI 50 response at week 12–16.</p><p>Regarding patients that switched to bimekizumab, a PASI 75/90 response was observed in 78.6/64.3% of the evaluated patients at 24 weeks while all three patients reaching 52 weeks of treatment had a clear skin (Table 2). After switching to brodalumab, PASI75/90 at 24 and 52 weeks was observed in 75/58.3% of the evaluated patients with 66.7% achieving great control of their disease with a PASI≤1 score at week 104. For patients that switched to ixekizumab, a PASI 75/90 was reached by 75/68.8% and 69.2/61.5% of patients at 24 and 52 weeks respectively. After 104 weeks, 71.4% achieved PASI≤1. Of the six patients switching to secukinumab, PASI75/90 response was observed in 83.3/50% after 24 weeks and 75/50% after 52 weeks.</p><p>During observation, three patients (2 receiving bimekizumab, and 1 receiving ixekizumab) experienced fungal infections (2 intertriginous infections and 1 stomatitis) that were promptly managed while no other serious
{"title":"Switching within the class of IL-17 inhibitors for the treatment of plaque psoriasis: A real-world retrospective study","authors":"Ioannis-Alexios Koumprentziotis MD, Natalia Rompoti MD, PhD, Irene Stefanaki MD, PhD, Charitomeni Vavouli MD, Marina Papoutsaki MD, PhD, Maria Politou MD, Alexander Stratigos MD, PhD, Electra Nicolaidou MD, PhD","doi":"10.1111/ajd.14396","DOIUrl":"10.1111/ajd.14396","url":null,"abstract":"<p>The blockade of the interleukin (IL)-17 signalling pathway has revolutionized the treatment of psoriasis with agents such as ixekizumab, and secukinumab (IL-17A inhibitors), brodalumab (IL-17 receptor inhibitor) and bimekizumab (IL-17A and IL-17F inhibitor). Still, primary or secondary failure is observed in some patients forcing us to decide whether we will proceed with an agent that is not an IL-17 inhibitor or perform an intraclass switch.<span><sup>1</sup></span> The available literature on switching between IL-17 inhibitors is generally limited and up to date there are no real-world studies reporting on patients switching to the most recently approved IL-17A/F inhibitor, bimekizumab.<span><sup>2-6</sup></span> Therefore, we aimed to assess whether switching from an IL-17 inhibitor to another (including switching to bimekizumab) is an effective and safe option in a real-world setting.</p><p>We conducted a single-centre, retrospective study of adult patients with moderate-to-severe plaque psoriasis that discontinued an IL-17 inhibitor and were subsequently switched to another agent within the same class. The follow-up period was 104 weeks, with the exception of those that switched to bimekizumab who were followed for up to 52 weeks due to bimekizumab's recent approval in our country.</p><p>In total, 61 patients (40 males, 21 females) were included in the study and their baseline characteristics are presented in Table 1. Twenty-one patients had switched to bimekizumab, 16 to brodalumab, 18 to ixekizumab and 6 to secukinumab. The reason for IL-17 inhibitor discontinuation was primary failure (14 patients), secondary failure (44 patients) and adverse events (AEs) (3 patients). Primary failure was defined as insufficient response (patients not achieving psoriasis area severity index (PASI) 50 at weeks 12–16), according to the medication dosing scheme. Secondary failure was defined as the loss of response of PASI >50% of initial value in a patient who had previously achieved PASI 50 response at week 12–16.</p><p>Regarding patients that switched to bimekizumab, a PASI 75/90 response was observed in 78.6/64.3% of the evaluated patients at 24 weeks while all three patients reaching 52 weeks of treatment had a clear skin (Table 2). After switching to brodalumab, PASI75/90 at 24 and 52 weeks was observed in 75/58.3% of the evaluated patients with 66.7% achieving great control of their disease with a PASI≤1 score at week 104. For patients that switched to ixekizumab, a PASI 75/90 was reached by 75/68.8% and 69.2/61.5% of patients at 24 and 52 weeks respectively. After 104 weeks, 71.4% achieved PASI≤1. Of the six patients switching to secukinumab, PASI75/90 response was observed in 83.3/50% after 24 weeks and 75/50% after 52 weeks.</p><p>During observation, three patients (2 receiving bimekizumab, and 1 receiving ixekizumab) experienced fungal infections (2 intertriginous infections and 1 stomatitis) that were promptly managed while no other serious","PeriodicalId":8638,"journal":{"name":"Australasian Journal of Dermatology","volume":"66 2","pages":"101-104"},"PeriodicalIF":2.2,"publicationDate":"2024-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/ajd.14396","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142812103","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}